• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Drop in Januvia sales













And Lilly just got their once weekly GLP1 approved. Yet another competitor to take market share

So true ... Lilly is ready to hire young, eager and ready to work for peanuts! Suspect the flood of Eli reps is happening but will be temporary. Flash fry and cool....then, let em go!

Get the products out build and glide as reps get a heave ho!
 








So true ... Lilly is ready to hire young, eager and ready to work for peanuts! Suspect the flood of Eli reps is happening but will be temporary. Flash fry and cool....then, let em go!

Get the products out build and glide as reps get a heave ho!

I hear this is the strategy and the reason why they don't hire beyond a mid level much lower than Merck salaries. Their old reps are getting some temporary elves for the truckload of product to be spread around for launch placements. To think the volume of reps they are churning out in six packs will be long term is delusional. It would mean big $$$$$$$ trouble! Take off your dunce cap.
 




My Januvia sales are falling steadily, but I'll keep sampling like the fool that my idiot CTL thinks I am. In her book, if you're not sampling, you're not working. What an idiot. She's Nero and Merck is Rome. Yes, it's burning.
 




My Januvia sales are falling steadily, but I'll keep sampling like the fool that my idiot CTL thinks I am. In her book, if you're not sampling, you're not working. What an idiot. She's Nero and Merck is Rome. Yes, it's burning.

no samples, no scripts. key resource. dont leave home without it!

reps who forget about samples can work without siggies and spend the day at the pool!

wise up.....work!
 




















no samples, no scripts. key resource. dont leave home without it!

reps who forget about samples can work without siggies and spend the day at the pool!

wise up.....work!

Reps favorite method for playin' hooky is playin' without samples! Its well known. Any rep who keeps skipping on orders and screwing up inventory will soon be awarded a special award. The "2014 Hooky Player of the Year"...rhinestone studded plaque will be issued with their long awaited pink slip!

Those picking up the slack for these slackers will be getting promotions...
 




Reps favorite method for playin' hooky is playin' without samples! Its well known. Any rep who keeps skipping on orders and screwing up inventory will soon be awarded a special award. The "2014 Hooky Player of the Year"...rhinestone studded plaque will be issued with their long awaited pink slip!

Those picking up the slack for these slackers will be getting promotions...

It's ludicrous how some equate "working" with "sampling". These are some mighty dumb people.
 




It's ludicrous how some equate "working" with "sampling". These are some mighty dumb people.

Sure thing. That is why so much is invested with samples!

9 out of 10 docs want the samples. Many demand them and some will not write without them. We all know it. If they're not in that closet and a close in efficacy and in-class competitor is prominently displayed and found in bountiful amounts you will be impacted....

Tell the sample department they are no longer needed by the reps....watch what happens to your numbers........and you!
 




Sure thing. That is why so much is invested with samples!

9 out of 10 docs want the samples. Many demand them and some will not write without them. We all know it. If they're not in that closet and a close in efficacy and in-class competitor is prominently displayed and found in bountiful amounts you will be impacted....

Tell the sample department they are no longer needed by the reps....watch what happens to your numbers........and you!

We're all doomed, with or without the samples, you idiot.
 
















It cracks me up that you have companies with a broad spectrum of therapy options such as AZ, Novo & Lily and yet Merck management is shocked that Merck is not #1 with Endos when asked which company do they consider the experts for treatment of type 2 diabetes. Reminds me of the days with Singulair and allergists before we got the Schering respiratory products. One trick pony. It also scares me to think about the revenue Merck lost once it lost Singulair. Is history about to repeat itself? Should we be concerned? If not, please tell me why not.